Kevin C. Conlon, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 - Magnuson Clinical Center, Room 3B38
- Bethesda, MD 20892
- 240-760-6087
- 301-480-4442
- conlonkc@mail.nih.gov
RESEARCH SUMMARY
Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.
Areas of Expertise
1) immunotherapy 2) IL-15
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Kevin C. Conlon, M.D.
Clinical Trials
Publications
Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas
Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia
Phase 1 trial of IL-15 trans presentation blockade using humanized Mikß1 mAb in patients with T-cell large granular lymphocytic leukemia
Biography
Kevin C. Conlon, M.D.
Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.
